Supporting Innovation through Scientific Advice
|
|
- Asher Kennedy
- 6 years ago
- Views:
Transcription
1 Supporting Innovation through Scientific Advice PEARRL Regulatory Science Symposium, 21 st June 2017, University College Cork HPRA Dr Peter Kiely
2 Disclaimer All views expressed in this presentation are my own and do not necessary represent the opinions of HPRA or any entity which I have been, currently am or will be affiliated to. I declare I have no conflicts of interest.
3 Overview Challenges for Drug Development/Access Scientific Advice (SA) - what is it & when should it be sought EMA SA -figures and incentives. National SA Conclusion
4 Challenges in Access to Novel Medicines in 2017 & Beyond (1/2) Ageing population Increasing burden of chronic illnesses Increasing complexity novel medicines/supply chain Significant developments in medicine and manufacturing
5 Challenges in Access to Novel Medicines in 2017 & Beyond (2/2) High cost of development of new technologies High and rising pharmaceutical expenses Effects of the economic crisis on healthcare spending
6 Regulatory Framework (1/2) Provides Scientific Advice Promotes harmonisation at international level Incentives to stimulate development Development of best practice for medicines evaluation and supervision in Europe European Medicines Agency (EMA) Involvement of patients, healthcare professionals, stakeholders Preparation of scientific guidelines Committees and working parties
7 Regulatory Framework (2/2) Health Products Regulatory Authority (HPRA) National interface with the EMA / participate in EMA procedures Representatives on Committees and Working Parties CHMP, COMP, CAT, PDCO, PRAC, HPMC National Innovation Office National Scientific Advice Clinical Trials HPRA Strategy
8 Scientific Advice (what is it?) Aim: to assist applicants in the development of new or existing medicinal products. Taking into account the current knowledge of a given condition, targeted patient population, existing treatment modalities and specificities of the product being developed. Directive 2001/83: In assembling the dossier: applicants shall also take into account the scientific guidelines relating to the quality, safety and efficacy. Guideline Deviations, Clarification or Absence Guidelines of limited scope: Provision of tailored product specific advice Novel drug development Unforeseen problems
9 Types of scientific advice Product-Specific Scientific Advice - should be about one medicinal product (or drug-device combination) only (majority of meetings are in this category) Broad Scope Scientific Advice - not product-specific, e.g. use of a new study design that is applicable in a disease area, a new manufacturing process to be used across a range of products, general discussion of clinical development in a particular area
10 Types of Scientific Advice (2/2) Joint Regulator and Payer Scientific Advice Regulator: enables product access to market. Payer: enables patient access to product. National Centre for Pharmacoeconomics (NCPE in IE) National Institute for Health and Care Excellence (NICE in UK) German Institute of Medical Documentation and Information (DIMDI) EMA parallel HTA, FDA meetings EMA tailored scientific advice pilot project in February 2017 to support the development of new biosimilar medicines
11 Qualifications of Novel Methodologies CHMP Qualification Opinions: The method can apply to nonclinical or to clinical studies, such as the use of a novel biomarker. open for public consultation by the scientific community before adoption. CHMP Qualification Advice: advice on protocols and methods that are intended to develop a novel method with the aim of moving towards qualification. Letter of Intent: drug biomarker qualification or clinical outcome assessment to EMA and FDA. Letters of Support: when the novel methodology under evaluation cannot yet be qualified but is shown to be promising based on preliminary data - aims to encourage data-sharing and to facilitate eventual qualification
12 EMA SCIENTIFIC ADVICE AND PROTOCOL ASSISTANCE REQUESTS RECEIVED TOTAL
13 EMA SCIENTIFIC ADVICE REQUESTS BY THERAPEUTIC AREA (2015)
14 Scientific Advice: When and Who? Interactions with Regulators Innovation Offices (EMA and NCA): novel medicine, device or manufacture Scientific Advice (EMA and NCA); any stage of development - can be broad scope ; not legally binding Clinical Trial Authorisation Applications (NCA): investigational medicinal products Marketing Authorisation Applications (EMA and NCA): centralised (biologicals, vaccines, certain chemicals, orphan), decentralised, national (chemicals)
15 SCIENTIFIC ADVICE REQUESTS BY AFFILIATION OF REQUESTER
16 CLINICAL-TRIAL PHASES OF SCIENTIFIC ADVICE REQUESTS ( ) EMA
17 EMA Incentives Total or partial fee reduction for Orphan medicinal products. Paediatric development Small and Medium enterprises Prime scheme
18 HPRA Scientific Advice The HPRA provides national scientific and regulatory advice to commercial and noncommercial entities. Further details are provided on the HPRA website:
19 National scientific advice Meeting at HPRA offices Respiratory medicine Rheumatology Obstetrics / Gynaecology Dermatology Radiopharmaceuticals Indications for Botulinum neurotoxins Endocrine and Gastrointestinal conditions Generic medicines and biosimilars areas 30 days after the meeting, written advice is issued HPRA also actively contributes to Scientific Advice at EU level Provides advice on Biopharma products
20 Conclusions Development of new medicines that address unmet medical needs and to meet challenges are essential Increase interaction at earlier development. Improve efficiencies ensuring data generated by sponsors is relevant for the needs of regulatory authorities/hta s.
21 Links EMA scientific advice =pages/regulation/general/general_content_ jsp HPRA National scientific and regulatory advice. latory-information/national-scientific-andregulatory-advice
Guide for National Scientific and Regulatory Advice
Guide for National Scientific and Regulatory Advice ADV-G0017-3 DATE 18 JULY 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS
More informationHPRA: Supporting Clinical Research in Ireland
HPRA: Supporting Clinical Research in Ireland Lorraine Nolan, Chief Executive, HPRA HRB CRCI launch Gibson Hotel, Dublin September 29 th 2016 Overview HPRA role HPRA Strategic Plan (2016 2020) Quality
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More informationExplanatory note on general fees payable to the European Medicines Agency
Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation
More informationWork programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board
18 December 2014 EMA/773839/2014 Rev. 1 Management Board Work programme 2015 Adopted by the Management Board on 18 December 2014 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationThe European Medicines Agency: a model of patient/consumer interaction
The European Medicines Agency: a model of patient/consumer interaction V International Conference on patient safety Juan García Burgos Head of Public Information and Stakeholder Networking - Medical Information
More informationCentralised Procedure and Scientific Advice: an Overview
Centralised Procedure and Scientific Advice: an Overview Andrea Laslop Head of Scientific Office AGES Medizinmarktaufsicht AGES Vienna 30/01/2018 Austrian Federal Office for Safety in Health Care www.basg.gv.at
More informationEU Regulation Review: challenges and opportunities for industry
EU Regulation Review: challenges and opportunities for industry Mia Bengtström, Pharma Industry Finland Nordic Pediatric Conference June 13,2017 Paediatric Regulation Consultation: EFPIA s answers general
More informationRoles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)
Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of
More information-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009
Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member
More informationRecommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation
2 March 2010 EMA/COMP/15893/2009 Final Committee for Orphan Medicinal Products (COMP) Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for
More informationAdaptive Pathways and PRIME: A True Acceleration of Drug Development and Approval?
BERICHTE + ANALYSEN + MEINUNGEN European Medicines Agency's Initiatives Adaptive Pathways and PRIME: A True Acceleration of Drug Development and Approval? The European Medicines Agency (EMA) has launched
More informationRegulatory Considerations and Trends Europe and the U.S.
Regulatory Considerations and Trends Europe and the U.S. Professor Kjell Strandberg MD PhD Chairman NDA Advisory Board, NDA Regulatory Science Ltd UK Former CPMP Member and Director General Medical Products
More informationFive years as EMA Liaison at US FDA
Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines
More informationMechanism of coordinated access to Orphan Medicinal Products. MoCA. NIHDI Belgium
Mechanism of coordinated access to Orphan Medicinal Products MoCA dr Ri DeRidder NIHDI Belgium Context The Issue: Delays and disparities in access to OMP s Decisions on Pricing and Reimbursement exclusive
More informationarena that impact on clinical development
RESEARCH DEVELOPMENT Changes in the regulatory arena that impact on clinical development 23 May 2011 Agenda Voluntary Harmonisation Procedure PIP and Paediatric requirements Changes to EudraCT and European
More informationEU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers
Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationKey concepts of the paediatric regulation and latest developments
Key concepts of the paediatric regulation and latest developments Paolo Tomasi, M.D. Ph.D. Head of Paediatric Medicines European Medicines Agency Presented by: Paolo Tomasi An agency of the European Union
More informationEMA pharmacovigilance system manual
13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000
More informationOrphan Drug Development Strategic considerations
Orphan Drug Development Strategic considerations Jan van Emous Regulatory Affairs Director Europe PGH Genzyme, a Sanofi company www.genzyme.com jan.vanemous@genzyme.com Regulatory Intelligence Orphan Drug
More information1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States
PRESS 17/6/2016 PRESS RELEASE Council of the European Union 1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States "The Council of the European
More informationFinal report on the adaptive pathways pilot
28 July 2016 EMA/276376/2016 European Medicines Agency Summary In March 2014 EMA launched a pilot project to explore the adaptive pathways approach, a scientific concept of medicines development and data
More informationRegulatory Requirements
Regulatory Requirements CTTI Quality by Design Workshop 28-29 Jan 2013 Rockville, MD Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency An agency of the European Union Disclaimer
More informationFINAL REPORT 17 th April
Ref. Ares(2014)3857065-19/11/2014 Process on Corporate Social Responsibility in the Field of Pharmaceuticals Platform on Access to Medicines in Europe Working Group on Mechanism of Coordinated Access to
More informationProcedure management of variations
Procedure management of variations Process changes made and current challenges Presented by Alberto Ganan and Iordanis Gravanis on 24 April 2015 Procedure Management Department An agency of the European
More informationAdoption by CHMP for release for 3-month public consultation 18 November End of consultation (deadline for comments) 28 February 2011
18 October 2012 EMA/651649/2010 Committee for Medicinal Products for Human Use Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative,
More informationIntroduction to the SmPC guideline
Introduction to the SmPC guideline SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group An
More informationAdvanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None
EAHP March 2016 Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4 Dr. Lenka Taylor Pharmacy University Hospital Heidelberg Disclosure Relevant Financial Relationships
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
17 December 2015 EMA/839636/2015 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Reflection paper on the chemical structure and properties criteria to be considered
More informationThe future clinical trial authorisation process: the new evaluation process
The future clinical trial authorisation process: the new evaluation process Massimiliano Sarra March 20 th 2017 Public Declaration of transparency/interests* The view and opinions expressed are those of
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationIncentives and Regulatory Considerations in Orphan Drug/Medical Device Development - Situation in Japan -
Incentives and Regulatory Considerations in Orphan Drug/Medical Device Development - Situation in Japan - MHLW/PMDA, Japan Speaker: Hiroshi Takeda Reviewer, Office of New Drug III, PMDA 1 Disclaimer The
More informationSurvey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia
20 October 2016 Stakeholders and Communication Division Survey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia 30 Churchill Place Canary Wharf
More informationJoint Horizon Scanning for pharmaceuticals
Joint Horizon Scanning for pharmaceuticals - KCE report and use of EMA data Irina Cleemput (KCE Belgium) Aldo Golja (Dutch ministry of Health) 1 BeNeLuxA Introduction Brood hal, Brussels BeNeLuxA what
More informationPublications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity
Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity OBJECTIVES FOR THE SESSION To be able to build payer evidence requirements into publication
More informationSaudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority
Saudi FDA Drug Approval Process Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority Objective Describe the drug regulation practice in Saudi Arabia and
More informationEuropean Medicines Agency Perspective
European Medicines Agency Perspective WMA Workshop on revision of DoH, 4-6 Dec 2012, Capetown, South Africa. Presented by: Fergus Sweeney, PhD Head of Sector, Compliance and Inspection, European Medicines
More informationModule 1: Administrative information Application form
7 September 2017 CMDh/332/2017/Rev.1 User guide for the electronic application form for a Marketing Authorisation Purpose and general rules This User guide has been prepared in order to facilitate the
More informationLaunching drug product in Europe Q&A
Launching drug product in Europe Q& David McCoubrey: Senior Regulatory ffairs Scientist, lmac Group Q& Launching drug product in Europe Q& David McCoubrey: Senior Regulatory ffairs Scientist, lmac Group
More informationEU Update on Regulatory Developments
EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Copenhagen, 4-6 May 2015 An agency of the European Union Overview International cooperation
More informationEU Clinical Trial Regulation A view from the Industry
Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty
More informationREQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:
Annex 1: Clinical trial Application Form REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE
More informationScientific Advisory Groups (SAG)
Scientific Advisory Groups (SAG) Experience and impact of patient involvement Presented by: Francesco Pignatti Human Medicines Evaluation Division, EMA Training session for patients and consumers involved
More informationUsing local RWD to drive global therapeutic advancements.
Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those
More informationThe importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016
The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 Marianne Kock, Head of Global Regulatory Affairs & Managing Director, Ferring Pharmaceuticals
More informationParallel Scientific Advice- TLV s perspective. Wing Cheng DIA Euromeeting Vienna 26th March 2014
Parallel Scientific Advice- TLV s perspective Wing Cheng DIA Euromeeting Vienna 26th March 2014 Overview History: Pilot project TLV-MPA National advice process TLVs experience: EMA-HTA and EUnetHTA Comparison
More informationSummary of the work programme for the. European Medicines Agency
European Medicines Agency EMEA/MB/44295/26 Summary of the work programme for the European Medicines Agency 27 This document provides a summary of the Agency s work programme 27. The Agency s full work
More informationEMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP)
EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP) European Health Forum - 3 rd October 2013 Falk Ehmann MD, PhD European Medicines Agency - London
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More informationVIVEK VIKRAM SINGH, SUBJECT MATTER EXPERT, RESEARCH & ANALYTICS CAN COMPETITIVE INTELLIGENCE STRATEGIES HELP IN ORPHAN DRUG DEVELOPMENT?
VIVEK VIKRAM SINGH, SUBJECT MATTER EXPERT, RESEARCH & ANALYTICS CAN COMPETITIVE INTELLIGENCE STRATEGIES HELP IN ORPHAN DRUG DEVELOPMENT? wns wns CAN COMPETITIVE INTELLIGENCE STRATEGIES HELP IN ORPHAN DRUG
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationGuide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland
Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland IA-G0008-5 17 JUNE 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance
More informationPharmabiotics: a Regulatory Hurdle in Europe
Pharmabiotics: a Regulatory Hurdle in Europe Dr. Magali Cordaillat-Simmons PRI Executive Scientist Raleigh, NC, USA September 8th, 2014 PHARMABIOTICS: A REGULATORY HURDLE IN EUROPE I. Introduction to Pharmabiotics
More informationRAC (EU) Examination Study Checklist
RAC (EU) Examination Study Checklist Instructions: Use this checklist to track your progress when preparing for the RAC (EU) certification examination. When you begin your studying, each task statement
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationFIFARMA Position: Transparency in regulatory decision making on the approval for biosimilar products
FIFARMA Position: Transparency in regulatory decision making on the approval for biosimilar products CASSS LATAM Forum, Sep 5-6, Mexico City Thomas Schreitmueller, Co-chair FIFARMA Regulatory and Biologics
More informationGuideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches
15 December 2016 EMA/CHMP/CVMP/JEG-3Rs/450091/2012 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on the principles of regulatory
More informationEU Orphan Drug Launch
EU Orphan Drug Launch Understanding and delivering your EU Orphan Drug Launch Almac Pharma Services EU Orphan Drug Launch Find out more at our website ebook contents Share me Section 1 The EU rare disease
More informationWMA Declaration of Helsinki - Ethical
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Download the PDF file Adopted by the 18 th WMA General Assembly, Helsinki, Finland, June 1964 and amended
More informationUtilizing Innovative Statistical Methods. Discussion Guide
Utilizing Innovative Statistical Methods and Trial Designs in Rare Disease Settings Discussion Guide Background Rare diseases are a complex and diverse set of conditions which, when taken together, affect
More informationAdaptive pathways workshop briefing book
Adaptive pathways workshop briefing book Readers guidance Follow us on Twitter #AdaptivePathways About this briefing book This document is preparatory reading material for the adaptive pathways workshop.
More informationQbD approach and Regulatory Challenges in Europe
QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views
More informationEuropean Medicines Agency post-authorisation procedural advice for users of the centralised procedure
11 December 2017 EMEA-H-19984/03 Rev. 75 Human Medicines Evaluation Division European Medicines Agency post-authorisation procedural advice for users of the This integrated version has been created for
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationDrug Development Services
Drug Development Services Speaker Introduction Nik Burlew Vice President Regulatory and Strategic Development 25 Years in Pharma: Development, MFG and QA. Consulting for the last 13 years primarily to
More informationQuestions And Answers To Support The
Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation
More informationProcedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products
02 May 2013.. Procedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products 7 Westferry Circus Canary Wharf London
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationEMA. François Houÿez. Director of Treatment Information & Access Eurordis Summer School 2012, Barcelona
Patients @ EMA François Houÿez Director of Treatment Information & Access Eurordis Summer School 2012, Barcelona Please comment (fictitious case) A pulmonary hypertension patients organisation collects
More informationReview of three years of Post Authorization Safety Studies (PASS) landscape under the 2010 European Pharmacovigilance
Review of three years of Post Authorization Safety Studies (PASS) landscape under the 2010 European Pharmacovigilance Pierre Engel Priscilla Velentgas May 2016 Copyright 2016 Quintiles Your presenters
More informationNon-clinical documentation Overview of Requirements
3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements
More informationICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories.
European Medicines Agency November 2007 EMEA/CHMP/ICH/437986/2006 ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories Step 5
More informationWork programme October 2017 EMA/583016/2016 Rev.1 1 Executive Director. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
9 October 2017 EMA/583016/2016 Rev.1 1 Executive Director 1 Project added to 2017 work programme, chapter 4: Support and governance activities 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationVISION 2015 EUROPEAN GENERIC MEDICINES ASSOCIATION
EUROPEAN GENERIC MEDICINES ASSOCIATION VISION 2015 THE EGA S THOUGHTS ON HOW TO IMPROVE THE LEGAL AND REGULATORY FRAMEWORK FOR GENERIC AND BIOSIMILAR MEDICINES www.egagenerics.com OCTOBER 2010 ENHANCE
More informationMedical Products between
Proactive Communications about Medical Products between Manufacturers and Payors FDLI Advertising & Promotion Conference September 27, 2017 David J. Bloch Principal Legal Counsel, Corporate Legal Regulatory
More informationEuropean Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
11 December 2017 EMA/821278/2015 Human Medicines Research and Development Support European Medicines Agency pre-authorisation procedural advice for users of the This integrated version has been created
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationEU Perspective on Regulatory Issues for Biologics
Oncology Biologics Development Primer 29 February 2008 Robert Charnas Disclosure Employee and shareholder of Amgen, Inc. Thousand Oaks, CA Worked in Basel, Switzerland for 19 Years and dealt with European
More informationComplex Generics: Charting a new path
White paper Complex Generics: Charting a new path Complex generics offer a lucrative market for drug manufacturers, but only if they can adapt to a more complicated and challenging development process.
More informationPREVIEW. Benchmarking European Investigator Payments Industry Standard Research
PREVIEW Benchmarking European Investigator Payments Info@ISRreports.com 2014 Industry Standard Research www.isrreports.com Report Overview This report provides an analysis of Europe s clinical trial compensation
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationDETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS
DETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS Korchagina D 1, Vataire AL 2, Toumi M 3, Falissard B 4, Aballéa S 2 ISPOR 18th Annual European Congress 1 University of Paris-Sud, Paris,
More informationQUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT
QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT Doc. Ref.: CMDh/274/2012, Rev3 NovemberRev4 December 2012 QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT... 1 Where can guidance and recommendations
More informationEarly Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development
Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.
More informationTHE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE
THE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE Ali Mohamadi, M.D. Senior Director, Global Regulatory Patient Engagement and Policy BioMarin Pharmaceutical 30-July-2016 Goals of Today s Presentation
More informationInsights into the Rare Disease Drug Approval Landscape: Trends and Current Development
Insights into the Rare Disease Drug Approval Landscape: Trends and Current Development Mike Lanthier Operations Research Analyst FDA Office of the Commissioner NORD Rare Diseases & Orphan Products Breakthrough
More informationMonthly statistics report: December 2017
19 January 2018 EMA/39932/2018 Information Management Division Medicinal products for human use (cumulative figures for the year to date) This document provides current information related to the volume
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationMandate and objectives for the EMA Working Party on Quality Review of Documents (QRD)
1 July 2014 EMA/403106/2014 Mandate and objectives for the EMA Working Party on Quality Review of Documents 1. General considerations The European Medicines Agency (EMA) created an ad hoc Working Group
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012
More informationEFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY
EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY PREAMBLE The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the
More information